On November 2, 2021 Beijing BeiGene reported a global collaboration to develop and commercialize four natural killer-based cell therapies discovered by San Diego’s Shoreline Biosciences (Press release, Shoreline Biosciences, NOV 2, 2021, View Source [SID1234594654]). BeiGene made a $45 million upfront payment and will be responsible for (unspecified) milestones, plus additional R&D funding and royalties. Shoreline is developing off-the-shelf, standardized and targeted natural killer and macrophage cellular immunotherapies, which it derives from induced pluripotent stem cells (iPSC), primarily for cancer. Today, Shoreline closed a $140 million B round led by Ally Bridge Group.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!